Giggle Incontinence

Original Editor - Rochelle DeSouza Top Contributors - Stacy Lawrence, Rochelle Dsouza and Ewa Jaraczewska

Introduction

Giggle incontinence (GI), also known as enuresis risoria or giggle micturition, is a rare condition characterised by the involuntary, sudden, and unpredictable loss of urine in response to laughter. This phenomenon typically results in the complete or near-complete emptying of the bladder, even if giggling ceases.

Due to the sensitive nature of GI, disclosure of symptoms is usually limited. Research on the condition is relatively small. Data on this type of incontinence is limited.

Epidemiology

GI predominantly affects children and adolescents, with a higher prevalence observed in pre-pubertal girls compared to boys. Most individuals tend to outgrow this condition by their teenage years.

Pathophysiology

While the exact pathophysiology remains unclear, several neurological and urological mechanisms have been proposed to explain the condition.

• Neurological Basis

The leading hypothesis suggests that GI is a form of cataplexy, a sudden loss of muscle tone triggered by emotional stimuli such as laughter. Cataplexy is commonly associated with narcolepsy, a sleep disorder characterised by dysregulation of the brain’s arousal and motor control centres. Some researchers propose that GI may result from transient dysfunction in the pontine micturition centre (PMC) and its connections to the brainstem and spinal cord. This theory suggests that during laughter, an exaggerated neurological response disrupts normal voluntary bladder control, leading to involuntary voiding.

• Autonomic Nervous System Dysregulation

GI may also be linked to an imbalance between the sympathetic and parasympathetic nervous systems. The parasympathetic nervous system is primarily responsible for bladder contraction via stimulation of the detrusor muscle through cholinergic pathways. In individuals with GI, sudden laughter may lead to excessive parasympathetic activation, overriding voluntary control of the external urethral sphincter and causing complete bladder emptying.

• Pelvic Floor and Urethral Sphincter Dysfunction

Unlike stress urinary incontinence, where weakened pelvic floor muscles contribute to urine leakage, GI occurs independently of typical stressors like coughing or sneezing. Some studies suggest that in affected individuals, there is transient inhibition of the external urethral sphincter during laughter, leading to an uncontrollable loss of urine. However, electromyographic (EMG) studies have shown that baseline pelvic floor function in patients with GI is often normal, indicating that the incontinence episodes are likely due to an abrupt neurological event rather than a structural deficiency.

Differential Diagnosis

When diagnosing GI, it is essential to distinguish it from other forms of urinary incontinence, such as:

• Stress Urinary Incontinence: Involuntary urine leakage during physical activities that increase intra-abdominal pressure, like coughing, sneezing, or exercising.
• Urge Urinary Incontinence': A sudden, intense urge to urinate followed by involuntary urine loss.
• Mixed Incontinence: A combination of stress and urge incontinence symptoms.

A thorough clinical history, physical examination, and evaluation of voiding patterns are crucial to accurately diagnose GI and exclude other potential causes of incontinence. ​

Management

Management strategies for GI encompass both conservative and medical approaches:

• Conservative / Physiotherapy Measures:
  • Standard Urotherapy: This includes education on proper voiding habits, maintaining a regular voiding schedule, and ensuring adequate fluid intake.
  • Pelvic Floor Muscle Training: Strengthening the pelvic floor muscles can enhance bladder control and reduce episodes of incontinence. ​
  • Biofeedback: This technique helps patients become aware of and control their pelvic floor muscles, thereby improving bladder function.

• Medical Treatment:
  • Methylphenidate: A central nervous system stimulant traditionally used to treat attention deficit hyperactivity disorder (ADHD), methylphenidate has shown efficacy in managing GI. However, while initial responses may be positive, there is a significant relapse rate, and sustained effectiveness varies among individuals.

Fernandes et al. highlights "regardless of GI severity, first-line treatment options could include reassurance of cure and timed voiding or bowel management, followed by biofeedback and Kegel exercises. Second-line treatment of oxybutynin with timed voiding could be tried, followed by third-line treatment with MPH. It should be noted that the latter option might be objectionable to many parents owing to its association with attention deficit hyperactivity disorder. "

Conclusion

Although uncommon, GI, can significantly impact a child's or adolescent's quality of life and self-esteem. Early recognition and a comprehensive, individualised treatment plan would be essential for effective management. A multidisciplinary approach, incorporating both physiotherapy and medical interventions, would help the social and psychological effects associated with this condition.